ALKS Stock: Alkermes plc Stock Price, Analysis & Insights
Get live alks stock price $28.06, comprehensive Alkermes plc stock analysis, charts, news, and expert forecast. Real-time alks stock data and investment insights.
Loading chart...
Company Overview
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Company Information
- CEO
- Richard F. Pops
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1800
Contact Information
- Website
- https://www.alkermes.com
- Address
- Connaught House
- Country
- IE
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 14.0)
✓ Lower volatility stock (Beta: 0.44) may provide portfolio stability
Business Model & Strategy
Alkermes plc operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Richard F. Pops, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Alkermes plc competes in the Biotechnology within the broader Healthcare. With 4.6 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Alkermes plc provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Alkermes plc should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Alkermes plc shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Alkermes plc
- ⚠Investors should consider how Alkermes plc fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
4.63B
P/E Ratio
13.96
Beta
0.44
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 4.63B market capitalization
- Trading Volume: 1.47M shares traded today
- Price Range: 52-week range of $25.17 - $36.45
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Alkermes plc
Alkermes plc (ALKS) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 4.63B, the company represents a significant player in its market. The stock is currently trading at $28.06 with a negativedaily change of 0.39%.
The company's 1800 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 13.96, beta of 0.44, and 52-week price range from $25.17 to $36.45when evaluating investment opportunities.
Why Invest in Alkermes plc?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Richard F. Pops
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.